Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Jefferson Research
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allergan Inc Wins Round In Patent Fight Over Lumigan-Reuters


Monday, 28 Jan 2013 04:48pm EST 

Reuters reported that Allergan Inc on a round in a patent fight against two generic drug makers on January 28, 2013 when an appeals court found a key portion of the patent for its glaucoma drug, Lumigan, was valid. The U.S. Court of Appeals for the Federal Circuit also ruled that Sandoz, the generic unit of Novartis AG, and Teva would infringe that patent if they went through with plans to sell a generic version of Lumigan. The appeals court upheld a decision from the U.S. Court of Appeals for the District of Delaware. 

Company Quote

212.63
0.45 +0.21%
19 Dec 2014